NEUROMYELITIS OPTICA SPECTRUM DISORDER
Clinical trials for NEUROMYELITIS OPTICA SPECTRUM DISORDER explained in plain language.
Never miss a new study
Get alerted when new NEUROMYELITIS OPTICA SPECTRUM DISORDER trials appear
Sign up with your email to follow new studies for NEUROMYELITIS OPTICA SPECTRUM DISORDER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Promising new treatment aims to stop devastating autoimmune attacks
Disease control OngoingThis study tests a drug called MIL62 in 102 adults with neuromyelitis optica spectrum disorder (NMOSD), a rare autoimmune disease that attacks the nerves in the eyes and spinal cord. The goal is to see if MIL62 can safely prevent relapses (sudden worsening of symptoms). Participa…
Matched conditions: NEUROMYELITIS OPTICA SPECTRUM DISORDER
Phase: PHASE3 • Sponsor: Beijing Mabworks Biotech Co., Ltd. • Aim: Disease control
Last updated May 17, 2026 04:19 UTC
-
New study tracks immune effects of Long-Term NMOSD drug
Disease control OngoingThis study looks at the long-term safety of inebilizumab, a drug for neuromyelitis optica spectrum disorder (NMOSD). It measures how the drug affects immune cells and antibody levels over time, and what happens when treatment stops. The study involves 32 adults who have already b…
Matched conditions: NEUROMYELITIS OPTICA SPECTRUM DISORDER
Phase: PHASE4 • Sponsor: Amgen • Aim: Disease control
Last updated May 12, 2026 13:41 UTC
-
New device aims to help NMOSD patients walk again
Symptom relief ENROLLING_BY_INVITATIONThis study tests a device called MR-C-014 to see if it is safe and acceptable for people with neuromyelitis optica spectrum disorder (NMOSD) who have trouble walking. About 30 adults aged 18-70 will use the device for 8 weeks, walking 3 times per week. Researchers will track how …
Matched conditions: NEUROMYELITIS OPTICA SPECTRUM DISORDER
Phase: NA • Sponsor: MedRhythms, Inc. • Aim: Symptom relief
Last updated May 17, 2026 04:35 UTC
-
Scientists launch Long-Term study to unravel mysteries of rare neuroimmune diseases
Knowledge-focused OngoingThis study follows 150 people with rare inflammatory conditions like neuromyelitis optica and transverse myelitis to learn what causes disease flares and why some treatments work better for certain patients. Participants continue their usual care while providing blood samples and…
Matched conditions: NEUROMYELITIS OPTICA SPECTRUM DISORDER
Sponsor: University of Texas Southwestern Medical Center • Aim: Knowledge-focused
Last updated May 15, 2026 11:55 UTC
-
New study aims to unlock the mysteries of rare autoimmune disease NMOSD
Knowledge-focused ENROLLING_BY_INVITATIONThis study is following about 800 adults with NMOSD across North America to learn more about the disease—how it starts, progresses, and is managed. Researchers will collect information from doctors and patients over time, but no new treatments are being tested. The goal is to imp…
Matched conditions: NEUROMYELITIS OPTICA SPECTRUM DISORDER
Sponsor: CorEvitas • Aim: Knowledge-focused
Last updated May 12, 2026 13:40 UTC